Navrogen Inc Press Releases - EIN Presswire - Press Release Distribution Service

Published on July 14, 2026 - 16:02 GMT

Navrogen Awarded Patent for NAV-001 Anti-Mesothelin Antibody-Drug Conjugate (ADC) Targeting Difficult-to-Treat Cancers

The patent covers the design and use of NAV-001 ADC to treat cancers where the therapeutic efficacy of antibody-based drugs, including ADCs, is immunosuppressed CHEYNEY, PA, UNITED STATES, July 14, 2026 /⁨EINPresswire.com⁩/ -- Cheyney, PA, July 14, 2026 …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on July 7, 2026 - 16:29 GMT

Navrogen Publishes Breakthrough on NAV-005, A CA125 Antagonist That Improves Antibody Cancer Therapy and ADC Efficacy

The research highlights how NAV-005 overcomes the immunosuppressive effects that tumor-produced CA125 has on antibodies and ADCs to enhance their efficacy PHILADELPHIA, PA, UNITED STATES, July 7, 2026 /⁨EINPresswire.com⁩/ -- Navrogen, Inc., a …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on January 20, 2026 - 13:00 GMT

Navrogen Granted Composition and Use Patent to Humoral Immuno-Oncology Factor Antagonist NAV-005 to Treat Cancer

CHEYNEY, PA, UNITED STATES, January 20, 2026 /⁨EINPresswire.com⁩/ -- Navrogen, Inc., a biopharmaceutical company specialized in developing antibody-based therapies and humoral immunosuppressive factor antagonists to treat cancer, announced today that the …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on October 30, 2025 - 11:58 GMT

Navrogen Granted Patents on Humoral Immuno-Oncology (HIO) Technology and HIO-Refractory NAV-001 Antibody-Drug Conjugate

CHEYNEY, PA, UNITED STATES, October 30, 2025 /⁨EINPresswire.com⁩/ -- Navrogen, Inc., a biopharmaceutical company specialized in developing antibody-based therapies for cancer, announced today that it has been granted patents by the European Patent Office ( …

Distribution channels: Healthcare & Pharmaceuticals Industry ...